Reply to Gibot by Oudhuis, Guy J. & Verbon, Annelies
Guy J. Oudhuis
Annelies Verbon
Reply to Gibot
Accepted: 23 April 2009
Published online: 19 June 2009
 The Author(s) 2009. This article is
published with open access at
Springerlink.com
This reply refers to the comment available
at: doi:10.1007/s00134-009-1547-8.
Dear Sir: Herewith we respond to
comments on our paper [1] made by
Dr. Gibot.
The fact that the study was performed
retrospectively is stated clearly, but it
was not reported explicitly that part
of the samples were used in a previ-
ous study [2]. All samples were stored
at -80C in different aliquots until
further processing. They were not
subject to freeze-thaw cycles, since
one aliquot was used in the study by
Linssen et al. [2] and a different
aliquot was used for our study.
Despite the fact that centrifugation
at 2509g for 10 min might not have
been sufﬁcient to eliminate all cells
present in the bronchoalveolar lavage
(BAL) ﬂuid, samples from the con-
ﬁrmed ventilator-associated
pneumonia (VAP) group and the
nonconﬁrmed VAP group were sub-
ject to the same procedure. Although
we cannot completely exclude that
persistence of cells expressing trig-
gering receptor expressed on myeloid
cells-1 (TREM-1) might have con-
founded results, it is unlikely that this
explains the lack of difference
between VAP and non-VAP, since
the mean cell count was higher in the
conﬁrmed VAP group (p\0.001).
In case of antibiotic use, percent-
age intracellular organisms (ICO,
C2%) will still be a reliable diag-
nostic tool for diagnosis of VAP [2].
The number of VAPs diagnosed using
ICO percentage and negative quanti-
tative culture was 16 of 97 cases
(17%). Since standard practice at our
intensive care unit (ICU) is to start
antibiotics after performance of BAL,
this suggests that no VAPs were
misdiagnosed due to prior antibiotic
use. The ﬁnal diagnosis in noncon-
ﬁrmed VAP patients could not be
retrospectively established in all
cases, but varied from acute respira-
tory distress syndrome (ARDS) to
Pneumocystis pneumonia (PCP).
Finally, we were not aware of the
fact that the assay was recalled by
R&D Systems, a fact for which we
apologise. However, the assay was
recalled because the kit had a bias
towards detection of recombinant
TREM-1, thereby underestimating
natural TREM-1 levels. Since the
recombinant TREM-1 was only used
to determine the standard concentra-
tions and was not used in the actual
assay, the underestimation occurred
in samples of both VAP and non-
VAP patients. Moreover, differences
in outcome between studies on the
diagnostic value of sTREM-1 may be
readily explained by factors other
than the assay itself, as stated in
Table 2 of our paper [1]. Three stud-
ies [3–5] indicated that sTREM-1
levels in BAL had potential for the
diagnosis of VAP [using immunoblot
or DuoSet enzyme-linked immuno-
sorbent assay (ELISA, R&D
Systems)], and three studies [1, 6, 7]
suggested that sTREM-1 levels in
BAL ﬂuid may not be helpful in
diagnosing VAP (using DuoSet or
Quantikine ELISA, R&D Systems).
Additionally, the number of cases, the
general everyday ICU setting, and the
correction for dilution of BAL and
type of BAL may have had a role in
the difference in outcome of the
studies.
In conclusion, in our opinion, this
study (despite its limitations) con-
tributes to the debate about the value
of sTREM-1 as a diagnostic marker
for VAP because the study was
performed in a large general ICU
population. This is the population in
which sTREM-1 should be used and
in which sTREM-1 levels may not be
helpful for clinicians to establish the
diagnosis of VAP.
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